Q-omics provides the consensus-scored SNCAIP profile across patient tissues and cancer cell-line models. SNCAIP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNCAIP is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SNCAIP RNA expression shows 17,818 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where SNCAIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNCAIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNCAIP survival associations across molecular data types. SNCAIP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNCAIP RNA expression–survival associations across cancer types. High SNCAIP expression shows unfavorable associations in UVM and KIRP, but favorable associations in KIRC, UCEC, ESCA and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNCAIP RNA expression.
This table summarizes SNCAIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SNCAIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNCAIP shows lower tumor expression in KIRC, UCEC, BRCA and KIRP and higher tumor expression in HNSC and LIHC. The KIRC box plot shows higher SNCAIP RNA expression in normal versus tumor tissue (log2 FC = −0.706, t-test p < 0.001).
This table shows molecular features associated with SNCAIP in patient tissues and cancer cell lines. In patient samples, SNCAIP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNCAIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LUNG_SCLC.
